Hedia
Hedia ApS is a Copenhagen-based digital therapeutics company that markets a CE-marked Class IIb medical device, the Hedia Diabetes Assistant, providing personalized insulin bolus dosing recommendations for people with insulin-requiring diabetes via HCP prescription, consumer app stores, and a Glooko integration.
- Company typePrivate
- Founded2016
- HeadquartersCopenhagen, Denmark
- Headcount11–50
- GTM typeB2C
- OfferingSoftware
What Hedia does
Hedia ApS is a Danish digital therapeutics company headquartered in Copenhagen that develops the Hedia Diabetes Assistant (HDA), a CE-marked Class IIb medical device designed to support self-management of insulin-requiring diabetes (primarily Type 1). The product functions as a personalized bolus calculator: it ingests structured inputs — blood glucose readings, carbohydrate intake, exercise, and active insulin — and applies optimization logic to generate insulin dosing recommendations and correction dosages. HDA was developed in collaboration with patients, nurses, and clinical stakeholders, and the company has published clinical studies demonstrating reduced hypoglycemia risk after 12 weeks and improved estimated A1c in users with suboptimal control.
The business operates on a B2B2C model with two primary distribution channels: (1) healthcare-provider-mediated prescription, where patients obtain access through clinics and hospitals across Denmark, the UK, Germany, and France, and (2) a partnership with Glooko that embeds Hedia's bolus calculator directly into the Glooko Mobile App, providing an additional channel through an established diabetes-management platform. The app is also available directly on iOS and Google Play. Revenue derives from subscription arrangements, though pricing is not publicly disclosed. Hedia raised a €3 million seed extension in February 2024 and has backing from Novo Nordisk heirs. The company appointed a new CEO, Rasmus Kofoed (ex-Novo Nordisk, Abbott, Roche, Medtronic), effective December 1, 2025, and has publicly targeted profitability by 2027 alongside an eventual sale to an industrial diabetes-care player.
Hedia firmographics
Firmographics- Name
- Hedia
- Legal name
- Hedia ApS
- Website
- https://hedia.co
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Hedia ApS is a Copenhagen-based digital therapeutics company that markets a CE-marked Class IIb medical device, the Hedia Diabetes Assistant, providing personalized insulin bolus dosing recommendations for people with insulin-requiring diabetes via HCP prescription, consumer app stores, and a Glooko integration.
- Ownership category
- akta.pro rank
Hedia industry classification
Industry- Product category
- Digital Therapeutics for Diabetes Management
- NAICS
- Computer Storage Device Manufacturing (334112)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators) (HLAHAHAJ)
- akta.pro secondary industries
- Blood Glucose Monitoring Devices (Consumer CGM & Smart Glucometers) (CRACAQAE), Blood Glucose Monitoring (BGM) Meters & Test Strips (HLAHAHAG)
Keywords
Where Hedia is headquartered
LocationHeadquarters
- HQ city
- Copenhagen
- HQ country
- Denmark
- HQ region
- Europe
Offices1 record
Markets served
Hedia business model
Business model- GTM type
- B2C
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- Digital Therapeutic Subscription: Hedia Diabetes Assistant is accessed through healthcare professionals. The app is provided as a prescription digital therapeutic with patients obtaining access via their healthcare provider.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Monthly | Healthcare provider-mediated access to Hedia Diabetes Assistant |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
Hedia product offering
Product offeringCore offering
Hedia develops and sells the Hedia Diabetes Assistant (HDA), a CE-marked Class IIb medical device delivered as a digital therapeutic mobile app. The product provides personalized insulin bolus calculations, correction dosages, active insulin tracking, and blood glucose management tools for people with insulin-requiring diabetes. Access is delivered through healthcare professional prescriptions, direct consumer app stores, and via integration within the Glooko Mobile App.
Product overview
Hedia is a Digital Therapeutics company offering a single core product, the Hedia Diabetes Assistant (HDA), a Class IIb medical device designed to support self-management of insulin-requiring diabetes. HDA provides a bolus calculator that delivers personalised insulin dosing recommendations based on blood glucose, carbohydrate intake, exercise, and active insulin data. The product is accessible through healthcare professionals and is available via the App Store and Google Play, with an integration partnership with Glooko enabling the bolus calculator to be available within the Glooko Mobile App.
Differentiator
Problem solved
Functional benefit
Products and services
- Hedia Diabetes Assistant (HDA) A CE-marked Class IIb medical device and digital therapeutic mobile app that provides a bolus calculator and personalized insulin dosing recommendations for people with insulin-requiring diabetes. It supports self-management of diabetes through data-driven decision support including blood glucose, carbohydrate intake, exercise, and active insulin tracking.
Quantifiable outcome
- Lowers risk of hypoglycemia in new users after 12 weeks
- +1 more outcomes
Companies that use Hedia
Customer profileNamed customers6 records
Segments2 records
Ideal customer profiles2 records
Hedia technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability2 records
Feature3 records
Hedia partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- GlookocoreHedia and Glooko partnered to integrate Hedia's bolus calculator directly into the Glooko Mobile App. This partnership delivers personalized insulin dosing advice, combining connected care, remote monitoring, and digital therapeutics to help people with type 1 and type 2 diabetes. The integrated solution was launched in the UK.
- Clinics and HospitalscoreHedia collaborates with a range of partners in the diabetes ecosystem, including clinics and hospitals that prescribe and distribute Hedia Diabetes Assistant to patients.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
Hedia competitors and assessment
Company assessmentDirect peers
- mySugr (Roche): mySugr is one of the most established diabetes self-management apps, now owned by Roche. It directly competes with Hedia Diabetes Assistant on bolus calculation, blood glucose tracking, and insulin logging for insulin-requiring patients in Europe.
- Glooko: Glooko offers a connected diabetes management platform aggregating data from CGMs, insulin pumps, and BG meters. It is both a partner (via bolus calculator integration) and a direct comparable, since its mobile app provides insulin management tools overlapping with Hedia's functionality.
- One Drop: One Drop is a digital health platform offering AI-powered blood glucose forecasting, insulin coaching, and self-management tools for people with diabetes. It competes directly with Hedia on the consumer/patient digital diabetes management side.
- Diabetes:M: Diabetes:M is a mobile diabetes management app providing bolus calculation, BG tracking, and insulin logging. It is a direct peer at the consumer app-store level, addressing the same insulin-requiring patient population as Hedia.
Broad incumbents
- Dexcom: Dexcom is a leading CGM manufacturer whose hardware-centric diabetes ecosystem increasingly embeds insulin dosing decision support. It is a broad incumbent shaping the digital diabetes landscape within which Hedia operates.
- Insulet: Insulet's Omnipod patch pump integrates with bolus calculator functionality and adjacent digital tools. It is a broad incumbent in the insulin delivery and management space, complementary to but competing for the same HCP channel.
- Medtronic Diabetes: Medtronic offers automated insulin delivery systems (MiniMed) with embedded bolus calculators. It is a broad incumbent in diabetes management whose integrated offerings overlap with Hedia's dosing decision support.
- Tandem Diabetes Care: Tandem offers t:slim insulin pumps with integrated bolus calculators and the t:connect mobile app. It is a broad incumbent providing digital insulin management tools to insulin-requiring patients in Europe and the US.
- Livongo (Teladoc Health): Livongo, now part of Teladoc Health, is a broad incumbent in chronic condition digital coaching including diabetes. It competes for HCP-prescribed digital therapeutic budgets and serves an overlapping patient population.
Emerging players
- Tidepool: Tidepool is a non-profit digital health platform supporting diabetes data visualization and insulin dosing workflows. It overlaps with Hedia's data-driven insulin management focus, particularly in the type 1 diabetes community.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Hedia social profiles
Digital presenceHedia compliance and trust
Trust signalCompliance2 records
Hedia financial estimates
Financial estimateRevenue estimate
Valuation estimate
Hedia leadership team
Management profileNumber of profiles
Profiles6 records
Hedia funding detail
Funding detailFunding overview
Funding rounds7 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Hedia M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Hedia
What does Hedia do?
Hedia develops and sells the Hedia Diabetes Assistant (HDA), a CE-marked Class IIb medical device delivered as a digital therapeutic mobile app. The product provides personalized insulin bolus calculations, correction dosages, active insulin tracking, and blood glucose management tools for people with insulin-requiring diabetes. Access is delivered through healthcare professional prescriptions, direct consumer app stores, and via integration within the Glooko Mobile App.
Is Hedia a public or private company?
Hedia is a private company. It is classified as venture growth investor backed and is currently operating.
When was Hedia founded?
Hedia was founded in 2016. It employs 11 to 50 people.
Where is Hedia based?
Hedia is headquartered in Copenhagen, Denmark, in the Europe region.
How does Hedia make money?
One revenue line is on record: digital Therapeutic Subscription.
Who are Hedia's main competitors?
Direct peers on record are mySugr (Roche), Glooko, One Drop and Diabetes:M. Broad incumbents are Dexcom, Insulet, Medtronic Diabetes, Tandem Diabetes Care and Livongo (Teladoc Health). Tidepool is listed as an emerging player.
Does Hedia have an API?
No public API is recorded for Hedia.
What industry is Hedia in?
Hedia's product category is Digital Therapeutics for Diabetes Management. Its primary akta.pro industry code is HLAHAHAJ, Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators), with a secondary code of CRACAQAE, Blood Glucose Monitoring Devices (Consumer CGM & Smart Glucometers). Its NAICS code is 334112 and its SIC code is 3841.